Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 8/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.39 |
| ▸ | CHRNG | P07510 | 4/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087100 | 0.84 | GNAI3 (0.40) | GNAI3GNAO1GNAI1PAOXSIRT6 | |
| SCHEMBL31087113 | 0.79 | SPHK1 (0.36) | — | |
| SCHEMBL30469018 | 0.76 | HDAC3 (0.31) | — | |
| SCHEMBL18165057 | 0.75 | PAOX (0.39) | PAOXSIRT6SIRT1CHRNDCHRNA1 | |
| SCHEMBL28646996 | 0.75 | TSHR (0.35) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL23805314 | 0.73 | HDAC3 (0.35) | — | |
| SCHEMBL18161922 | 0.72 | HDAC3 (0.35) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL25682469 | 0.72 | L3MBTL1 (0.34) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL30469023 | 0.71 | CPB2 (0.39) | — | |
| SCHEMBL31087111 | 0.70 | PAOX (0.44) | PAOXGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | GNAI3 3096/4885GNAO1 3674/4885GNAI1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.